Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The gut microbiome ecosystem provides colonization resistance against Clostridioides difficile through a complex network of microbial interactions and metabolic processes. In a healthy state, commensal bacteria compete for limited nutrients and produce metabolites, such as short-chain fatty acids and secondary bile acids, that inhibit the germination and vegetative growth of C. difficile (Buffie et al., 2015; Theriot et al., 2016). Disruption of this ecosystem, typically by broad-spectrum antibiotics, creates a niche that allows C. difficile to proliferate and release toxins, leading to severe diarrhea and colitis (Seekatz & Young, 2014). Therapeutic strategies targeting this ecosystem aim to restore microbial diversity and functional pathways rather than targeting a single receptor. Modern interventions include fecal microbiota transplantation (FMT) and defined live biotherapeutic products (LBPs) like Vowst and Rebyota, which have been FDA-approved to prevent recurrent C. difficile infection (Feuerstadt et al., 2022; Khanna et al., 2022). These therapies work by re-establishing the ecological balance required to suppress pathogen expansion and restore intestinal homeostasis.
Restoration of microbial diversity to provide competitive exclusion of Clostridioides difficile, restoration of secondary bile acid metabolism to inhibit spore germination, and production of short-chain fatty acids to maintain epithelial barrier integrity.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gut microbiome ecosystem (Clostridioides difficile colonization resistance).